Abstract
At a news conference at its headquarters in Rockville, Md., last week, Celera Genomics announced that it has completed a draft sequence covering almost the entire human genome. The sequencing effort, launched just last September, used a shotgun approach to analyze millions of random DNA fragments generated by shattering the genome's complement of chromosomes. Our statistical analysis and various methods of examining the genome indicate that we now have over 97% of all human genes in our database, observed J. Craig Venter, the company's president and chief scientific officer. Stock in the firm, which is owned by PE Corp., shot up 29% on the day of the announcement to close at $241 per share. It has since eased back somewhat, but the price has tripled since the end of November because investors hope that genome data will lead to new drugs and disease treatments. Celera's shotgun strategy has produced 10 million very high quality sequences ...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call